MEDIA RELEASE PR36286
aTyr Pharma to Present at Japan Biopharma Partnering Conference
SAN DIEGO, Calif., Sept. 30 /PRNewswire-AsiaNet/ --
Jeff Watkins, CEO, Scheduled for Podium Presentation on Tuesday 6 October 2009
aTyr Pharma, Inc., a biopharmaceutical company discovering and developing a new class of naturally occurring
proteins as biotherapeutics, will present at the Japan Biopharma Conference in Tokyo on Tuesday October 6. Jeff
Watkins, CEO of aTyr Pharma, will provide an overview of aTyr Pharma's technology, product engine, and lead
program based on naturally occurring resected proteins of the tRNA synthetases. The aminoacyl tRNA synthetases
are universal and essential elements of the protein synthesis machinery found in all organisms, but human
synthetases and their associated proteins have naturally occurring resected variants, called "resectins," with potent
cell signaling activities that are vital to normal functioning of humans. The resectins' activities are distinct from the
protein synthesis activities commonly known for synthetases, and aTyr Pharma is discovering and developing
the resectins as new biotherapeutic agents that can be used to treat a wide variety of human diseases including
inflammatory, autoimmune, hematopoietic and metabolic disorders.
According to Cheryl Quinn, Director of Business Development at aTyr Pharma, "Our broad multi-asset portfolio
of novel biotherapeutics can help pharmaceutical companies rapidly build out their biologics pipeline. We look
forward to taking part in the Japan Biopharma conference, as well as meeting potential partners from Japan and
Asia and to explore mutually beneficial opportunities."
About aTyr Pharma
aTyr Pharma, Inc. is a biopharmaceutical company focused on the discovery and development of an entirely new
class of biologics. aTyr Pharma's discovery engine for new biotherapeutics consists of novel proteins in the
family of tRNA synthetases with cell signaling activities distinct from the protein synthesis activities commonly
associated with the tRNA synthetases. These resected proteins, or "resectins," are being developed as novel
therapeutics to treat hematological disorders, neurodegenerative diseases, inflammation, cardiovascular diseases
and metabolic disorders.
SOURCE: aTyr Pharma, Inc.
CONTACT: Cheryl Quinn,
Director of Business Development of aTyr Pharma, Inc.,
+1-858-731-8390,
cquinn@atyrpharma.com;
or Media,
Jennifer James of Alta Partners,
+1-415-362-4022,
jjames@altapartners.com,
for aTyr Pharma, Inc.
NEWS 
